Categories Earnings, Health Care

Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot

— Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61.

— Total revenue stood at $1.96 million vs. $3.68 million expected.

Earnings Update by AlphaStreet

— Sage expects revenue growth of ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD), will be modest over the next couple of quarters with an increase in the rate of growth of ZULRESSO revenue anticipated in the second half of 2020.

— The company will be having a meeting with the FDA in the first quarter of 2020 to discuss about Zuranolone, the clinical program for the treatment of major depressive disorder (MDD) and PPD.

— R&D expenses were $91.3 million compared to $88.8 million in the prior-year quarter. SG&A expenses were $85.1 million vs. $75.7 million in the fourth quarter of 2018.

— SAGE stock, which ended down 1.24% at $63.65, had dropped 12% so far this year.

Listen to on-demand earnings calls and hear how management responds to analysts’ questions

Most Popular

Coca-Cola (KO) Q1 2021 earnings release

The Coca-Cola Company (NYSE: KO) reported first-quarter 2021 financial results before the regular market hours on Monday. The beverage manufacturer reported fourth-quarter revenue of $9 billion, up 5% year-over-year. The

Earnings calendar for the week of April 19

The market rally gathered pace this week amid impressive quarterly results, led by the banking sector, and positive economic data. Leading stock indexes continued their winning streak, with S&P 500

Undeterred by crisis, Bank of America stays in expansion mode

Leading Wall Street banks recorded robust earnings in the early months of fiscal 2021 with the results benefiting from the release of credit loss reserves, in most cases. Taking advantage

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top